Avasimibe

• Catalog No.: PZ0190
• CAS Number: 166518-60-1
• M. F.: C29H43NO4S
• M. W.: 501.72102
• Purity: ≥98% (HPLC)

SYNONYMS

• IUPAC name: 1-({[2,6-bis(propan-2-yl)phenoxy]sulfonyl}amino)-2-[2,4,6-tris(propan-2-yl)phenyl]ethan-1-one
• IUPAC Traditional name: 1-[(2,6-diisopropylphenoxysulfonyl)amino]-2-(2,4,6-triisopropylphenyl)ethanone
• Synonyms: CI-1011; PD 148515; [[2,4,6-tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl)phenyl ester] sulfamic acid

DATABASE IDS

• MDL Number: MFCD00934956
• CAS Number: 166518-60-1

PROPERTIES

• Empirical Formula (Hill Notation): C29H43NO4S
• Purity: ≥98% (HPLC)
• Apperance: white to tan powder
• Solubility: DMSO: ≥40 mg/mL
• Storage Temperature: room temp
• German water hazard class: 3

DETAILS

Description (English)

Legal Information
Sold for research purposes under agreement from Pfizer Inc.
Biochem/physiol Actions
Avasimibe (CI-1011) is an orally bioavailable Acyl-CoA:Cholesterol O-Acyltransferase (ACAT) inhibitor. It was originally developed as an antilepic drug, and was shown to significantly reduce plasma total triglyceride and VLDL-cholesterol, but later clinical trials were disappointing. ACAT has also been investigated as a potential therapeutic target for Alzheimer′s disease. Recent studies have looked at the effects of avasimibe in reducing amyloid pathology by limiting generation and increasing clearance of diffusible amyloid-beta (Abeta).

Description (简体中文)

Legal Information
Sold for research purposes under agreement from Pfizer Inc.
Biochem/physiol Actions
Avasimibe (CI-1011) is an orally bioavailable Acyl-CoA:Cholesterol O-Acyltransferase (ACAT) inhibitor. It was originally developed as an antilepic drug, and was shown to significantly reduce plasma total triglyceride and VLDL-cholesterol, but later clinical trials were disappointing. ACAT has also been investigated as a potential therapeutic target for Alzheimer′s disease. Recent studies have looked at the effects of avasimibe in reducing amyloid pathology by limiting generation and increasing clearance of diffusible amyloid-beta (Abeta).